<DOC>
	<DOCNO>NCT00198250</DOCNO>
	<brief_summary>The purpose study evaluate Venlafaxine treatment option hot flash breast cancer survivor . The goal study assess effectiveness toxicity venlafaxine hydrochloride identify psychological , behavioral , physical outcome associated relief hot flash woman follow treatment breast cancer .</brief_summary>
	<brief_title>Venlafaxine Hot Flashes After Breast Cancer</brief_title>
	<detailed_description>Hot flash severe fourth prevalent menopausal symptom report woman breast cancer . Hot flash affect 65 % population , 59 % rating symptom severe 44 % reporting extremely distressed symptom . Despite high prevalence , severity distress associate symptom , scientific basis manage hot flash woman breast cancer limit . This randomized , double-blind , placebo-controlled crossover trial examines effectiveness toxicity sustain release venlafaxine hydrochloride ( 37.5 mg po qd ) hot flash woman follow treatment breast cancer . Venlafaxine phenylethylamine derivative potently inhibits reuptake neuronal serotonin norepinephrine weakly inhibits reuptake dopamine . A secondary aim project examine impact hot flash psychological , behavioral , physical outcome . This study base Wickham Symptom Management Model depict interrelationship symptom , symptom management strategy , symptom management outcome . Participants ( n = 80 ) least one month post-completion surgery , radiation , and/or chemotherapy tamoxifen ( prescribe ) least six week complete two-week baseline hot flash assessment randomize one arm crossover trial . At end first six-week arm , participant crossover opposite study arm additional six week . Outcomes assess include effectiveness intervention ( hot flash frequency , severity , distress magnitude ) , toxicity intervention ( subjective preference , side effect ) , psychological outcome ( mood disturbance ) , behavioral outcome ( quality life , interference daily activity ) physical outcome ( fatigue sleep disturbance ) . Hot flash measure daily , use subjective , prospective diary methodology , weekly , use objective state-of-the art 24-hour physiological monitoring sternal skin conductance . Other outcome measure weekly . Compliance intervention/placebo assess weekly use medication blister pack card . Timing outcome assessment base limitation physiological monitoring device expect timing treatment effect . Summary statistic ( i.e. , mean , slope , maximum response , range , proportion , achievable difference ) use effectively reduce design 2 X 2 crossover data analyze accordingly ( i.e. , t-tests , linear regression , GEE , mixed model ) . Study finding significantly contribute scientific basis hot flash management woman follow treatment breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>woman least 21 year age willing able provide inform consent first time diagnosis breast cancer history cancer consider disease free time study enrollment least four week postcompletion surgery , radiation , and/or chemotherapy nonmetastatic cancer experience daily hot flash desirous treatment hot flash , concurrently use hot flash treatment live within 60 mile Indianapolis able read , write speak English current treatment antidepressant depression , neuropathic pain hot flash diagnosis metastatic breast cancer ( stage IV ) treatment hot flash within past four week , include ( ) soy supplement ; ( b ) botanical , dong quai ( Angelica sinensis ) , black cohosh , ginseng , gotu kola , licorice root , chaste tree , sage , wild yam root ; ( c ) vitamin E ; ( ) prescription medication , clonidine hydrochloride megestrol acetate .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Breast cancer survivorship</keyword>
	<keyword>hot flash</keyword>
	<keyword>treatment</keyword>
</DOC>